



Provider Newsflash



A fax bulletin for the Molina Healthcare of Washington Provider Network

Proton Pump Inhibitors (PPIs) Prior Authorizations (Medicaid)

Dear Pharmacy:

If your customer needs to continue a Proton Pump Inhibitor (PPI) medication, **please ask the prescriber to submit a prior authorization (PA) request to Molina Healthcare with supporting documentation.**

If you do not have supporting clinical documentation, please do not send Molina a PA request. Without clinical information from the prescriber we are unable to conduct a clinical review which delays treatment to the member. Clinical documentation includes previous medications tried/failed, specific diagnosis documented in the medical record, and/or concurrent treatments and their associated diagnosis.

If you would like more information on the Washington State Health Care Authority's Medicaid PPI Policy, please visit the policy webpage: <https://www.hca.wa.gov/billers-providers-partners/programs-and-services/apple-health-medicaid-drug-coverage-criteria>

Thank you for your continued service to Molina members.

Pharmacy network participation varies by plan.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711 and/or fax the opt-out request to 401-652-0893, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt. An opt out request will not opt you out of purely informational, non-advertisements, Caremark pharmacy communications such as new implementation notices, formulary changes, point-of sale issues, network enrollment forms, and amendments to the Provider Manual.

This communication and any attachments may contain confidential information. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents, is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual.